REGENERON PHARMACEUTICALS, INC. - FORM 10-K - EX-23.1 - CONSENT OF PRICEWATERHOUSECOOPERS LLP - February 7, 2020

Attached files

file filename
EX-32 - CERTIFICATION OF CEO AND CFO PURSUANT TO 18 U.S.C. SECTION 1350 - REGENERON PHARMACEUTICALS, INC.regn-ex32x12312019x10k.htm
EX-10.2.22 - PERFORMANCE RESTRICTED STOCK UNIT AGREEMENT - REGENERON PHARMACEUTICALS, INC.regn-ex10222ar2014ltip.htm
10-K - FORM 10-K - REGENERON PHARMACEUTICALS, INC.regn-123119x10k.htm
EX-31.2 - CERTIFICATION OF CFO PURSUANT TO RULE 13A-14(A) - REGENERON PHARMACEUTICALS, INC.regn-ex312x12312019x10k.htm
EX-31.1 - CERTIFICATION OF CEO PURSUANT TO RULE 13A-14(A) - REGENERON PHARMACEUTICALS, INC.regn-ex311x12312019x10k.htm
EX-21.1 - SUBSIDIARIES OF REGENERON PHARMACEUTICALS, INC. - REGENERON PHARMACEUTICALS, INC.regn-ex211x12312019x10k.htm
EX-10.10.2 - SECOND AMENDMENT AGREEMENT TO BAYER LCA - REGENERON PHARMACEUTICALS, INC.regn-ex10102secondamen.htm
EX-10.2.21 - RESTRICTED STOCK UNIT AGREEMENT - NON-EMPLOYEE DIRECTORS - REGENERON PHARMACEUTICALS, INC.regn-ex10221ar2014ltip.htm
EX-10.2.20 - STOCK OPTION AGREEMENT (NQ) - NON-EMPLOYEE DIRECTORS - REGENERON PHARMACEUTICALS, INC.regn-ex10220ar2014ltip.htm
EX-10.2.19 - RESTRICTED STOCK AGREEMENT - EXECUTIVE OFFICERS - REGENERON PHARMACEUTICALS, INC.regn-ex10219ar2014ltip.htm
EX-10.2.18 - STOCK OPTION AGREEMENT (NQ) - P. ROY VAGELOS - REGENERON PHARMACEUTICALS, INC.regn-ex10218ar2014ltip.htm
EX-10.2.17 - STOCK OPTION AGREEMENT (NQ) - EXECUTIVE OFFICERS - REGENERON PHARMACEUTICALS, INC.regn-ex10217ar2014ltip.htm
EX-4.1 - DESCRIPTION OF SECURITIES - REGENERON PHARMACEUTICALS, INC.regn-ex41xdescriptiono.htm


Exhibit 23.1


CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-228352) and S‑8 (Nos. 333-61132, 333-97375, 333-119257, 333-151941, 333-169569, 333-174863, 333-196799, 333-198794, and 333-218669) of Regeneron Pharmaceuticals, Inc., of our report dated February 7, 2020 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10‑K.


/s/ PricewaterhouseCoopers LLP

Florham Park, New Jersey
February 7, 2020




REGENERON PHARMACEUTICALS, INC. Reports